Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
John Carroll Murray
Professor of Dermatology
Dermatology
murra013@mc.duke.edu
2234 Crooked Creek Pkwy, Durham, NC 27713
234 Crooked Creek Pkwy, Durham, NC 27713
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Previous Appointments & Affiliations
expertise {hide_children: true, active: false, enabled: false}
Expertise
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: false}
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: false}
Recognition
professional-activities {hide_children: true, active: false, enabled: false}
Professional Activities
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
ESK-001-016 ONWARD1: A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis
Clinical Trial
Principal Investigator ·
Awarded by Alumis Inc. ·
2024 - 2029
A Phase 3, Randomized, Multicenter, Double Blind, Placebo and Active Comparator-Controlled Study with a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in subjects with moderate to severe
Clinical Trial
Principal Investigator ·
Awarded by Takeda Development Center Americas, Inc ·
2023 - 2026
Evaluation of the effect of moisturizers on the absorption of metronidazole and ivermectin into the stratum corneum of rosacea patients with tape stripping and liquid chromatography mass spectrometry
Research
Co Investigator ·
Awarded by National Rosacea Society ·
2023 - 2025
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986322 in Participants with Moderate-to-Severe Psoriasis
Clinical Trial
Principal Investigator ·
Awarded by Bristol-Myers Squibb Company ·
2023 - 2024
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
Clinical Trial
Principal Investigator ·
Awarded by Galderma ·
2020 - 2022
A phase 3 pivotal study (118161/118169) and open-label extension (118163) to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subjects and associated pr
Clinical Trial
Principal Investigator ·
Awarded by Galderma ·
2020 - 2022
Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to severe Palmoplantar Pustulosis (PPP)
Clinical Trial
Principal Investigator ·
Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. ·
2019 - 2021
Targeting Immune Dysregulation in Psoriasis
Research
Physician ·
Awarded by SILAB ·
2017 - 2021
Corrona Psoriasis Registry (Corrona-PSO-500)
Clinical Trial
Principal Investigator ·
Awarded by Corrona, Inc. ·
2015 - 2020
A Multi-Center, Randomized, Double-Blind, Placebo-and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
Clinical Trial
Principal Investigator ·
Awarded by Bristol-Myers Squibb Company ·
2019 - 2020
BI 655066 versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe cHronic plAque psoriasis evaluatiNg the effiCacy and safety with randomized withdrawal and rE-treatment (IMMhance)
Clinical Trial
Principal Investigator ·
Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. ·
2016 - 2020
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE PSORIASIS.
Clinical Trial
Principal Investigator ·
Awarded by Pfizer, Inc. ·
2015 - 2016
